Woodland Pharmaceuticals is a contract research organization dedicated to improving the cancer drug discovery process through the use of innovative oncology models. We have over 180 human cancer cell lines and access to primary patient tumor models. But unlike most other Oncology Contact Research Organizations (CROs), we are different:
We are focused on building a collection of tumor cell lines and primary tumors that are refractory to primary
standard of care (SOC) therapies. Modeling what your drugs will face as you enter the clinic. Not primary disease, but recurrent, refractory cancers.
Of course, we perform standard tumor growth inhibition/regression assays and more complex PK/PD modeling in naïve cells as well.